Pharmaceutical company Humanetics Corporation said on Wednesday that it has entered into an agreement with Swiss company DSM Nutritional Products Ltd to acquire all of its assets related to the manufacture of the active pharmaceutical ingredient (API) in the BIO 300 radioprotectant drug.

BIO 300 is a clinical-stage drug being developed by Humanetics for oncology and biodefense applications.

The acquisition includes patents, trademarks, trade secret manufacturing processes, analytical methods, regulatory filings and a large number of non-clinical and clinical safety studies.

Following the acquisition, Humanetics plans to transfer the manufacturing process to a site in the US.

BIO 300 is under development to protect normal tissues from the harm caused by radiation. The drug's radioprotective effects were originally discovered by researchers within the US Department of Defense at the Armed Forces Radiobiology Research Institute.

Humanetics has received federal funding to continue advancement of BIO 300 toward US FDA approval and has launched clinical studies for the use of BIO 300 to reduce the toxicity of radiation used in cancer treatment.